Artemis Alpha | ATS


Peers Price Chg Day Year Date
3i Infrastructure 355.00 3.50 1.00% 2.45% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Hikma Pharmaceutical 1,720.00 -3.00 -0.17% -12.07% Sep/05


Artemis Alpha traded at 358.00 this Tuesday April 9th, increasing 6.00 or 1.70 percent since the previous trading session. Looking back, over the last four weeks, Artemis Alpha gained 5.76 percent. Over the last 12 months, its price rose by 16.23 percent. Looking ahead, we forecast Artemis Alpha to be priced at 356.07 by the end of this quarter and at 350.33 in one year, according to Trading Economics global macro models projections and analysts expectations.

Artemis Alpha Trust plc is an investment trust. The Company's investment objective is to provide long-term capital and income growth by investing predominantly in listed companies and to achieve a net asset value total return. The Company's financial instruments consist of equities, derivatives, cash balances, as well as debtors and creditors that arise from its operations. The Company also invests in unquoted companies. The Company's investment portfolio includes sectors, such as consumer discretionary, financials, technology, industrials, health care, consumer staples, real estate, energy and basic materials, among others. Its portfolio of investments spans various geographies, such as United Kingdom, Germany, Jersey, Israel, Japan, Ireland, France, Netherlands, Cayman Islands, United States, Isle of Man and Australia, among others. Artemis Fund Managers Limited is the investment manager of the Company.